The mitochondrial disease therapy developer's latest round was co-led by Novo Ventures and backed by returning investor Lundbeckfonden Ventures.
Pharmaceutical firm Novo co-led a $95m series B round for US-based mitochondrial disease drug developer Reneo Pharmaceuticals on Wednesday through corporate venture capital unit Novo Ventures.
The round was co-led by life sciences investment firm Abingworth and included pharmaceutical company Lundbeck’s VC arm, Lundbeckfonden Ventures, as well as New Enterprise Associates (NEA), RiverVest Venture Partners, Pappas Capital, Rock Springs Capital, Aisling Capital and Amzak Health.
Reneo is working on therapeutics for diseases associated with the mitochondria, the parts of cells…
